Nektar Therapeutics <NKTR.O>: JPMorgan resumes coverage with neutral rating; target price $65
NKTR•Related News
Focus-From euphoria to despair, Korea reckons with stock mania's emotional toll
EWY•
US teen drops lawsuit against Meta, Google and Snap ahead of trial
META•
Walmart Inc <WMT.O>: D.A. Davidson cuts target price to $132 from $150
WMT•
Ships passing through Hormuz hover in single digits, data shows
XLE•
Advance Auto Parts Inc <AAP.N>: TD Cowen cuts target price to $45 from $61
AAP•